摘要
目的探讨大剂量柔红霉素在成人急性髓细胞白血病诱导治疗中的临床疗效。方法柔红霉素60 mg/m2,第1～3天,联合阿糖胞苷150 mg/m2,第1～7天,诱导治疗成人急性髓细胞白血病患者7例。结果 7例患者经第一次诱导化疗后4例达到完全缓解,2例未缓解,1例死亡,完全缓解率57%。结论大剂量柔红霉素[60～90 mg/(m2.d)]应用于国内成人急性髓细胞白血病诱导治疗疗效与常规剂量柔红霉素[45～50 mg/(m2.d)]相近,而血液学毒副反应大,无明显的心脏毒副反应增加。
Objective To evaluate the efficacy of large dose Daunorubicin in induction therapy for adult acute myeloid leukemia （AML）. Methods Seven cases of adult AML patients received induction therapy with Daunorubicin （60 mg/m2 q. d, 1 -3 d） plus Cytarabine （ 150 mg/m2 q. d, 1 - 7 d）. Results Complete remission （CR） was found in 4 patients after the first course of chemotherapy, while non-remission （NR） was found in 2 cases. The rest one died. The rate of CR was 57%. Conclusion The efficacy of large dose Daunorubicin （60 - 90 mg/m2. d） is close to that of standard dose Daunorubicin （45 - 50 mg/m2. d） in induction therapy for domestic adult AML with no notable increase of cardiac toxicity but greater hematological side effect.
出处
《实用医院临床杂志》
2012年第1期78-79,共2页
Practical Journal of Clinical Medicine
